Laboratory Head in Cardiovascular Pharmacology at Monash University, currently holding the prestigious positions of National Heart Foundation Future Fellow and Monash Talent Accelerator Fellow. Upon completing her PhD at the Department of Pharmacology & Therapeutics and the School of Chemistry (University of Melbourne), Dr. Qin advanced her career with a post-doctoral position at the Baker Institute in 2011. Recognizing her talent and leadership, she was subsequently recruited to establish her independent laboratory within the Drug Discovery Biology Theme at the Monash Institute of Pharmaceutical Sciences in 2019. Previously, she served as an MRFF REDI Industry Fellow and Baker Fellow. Dr. Qin also plays an integral role on the Board of Directors of the Australasian Pharmacologists and Toxicology Society, the Global Academic Drug Discovery Consortium, and the Australian Cardiovascular Alliance Emerging Leader (Industry Engagement portfolio). Dr. Qin is an emerging leader in translational pharmacology, driven by a visionary pursuit to develop "pro-resolving medicines" for the treatment of cardiopulmonary diseases, one of the leading causes of death globally. Her research team is dedicated to pioneering innovative "pro-resolving" therapies, primarily focusing on advancing the pro-resolving GPCRs (e.g. FPR2) R&D program to bridge scientific discoveries with impactful clinical solutions. Dr. Qin's expertise spans molecular and integrative pharmacology, rational drug design, and the intricacies of commercialization. Her scholarly contributions have been featured in prestigious journals such as Nature Communications, Cardiovascular Research, Circulation, British Journal of Pharmacology, Journal of Medicinal Chemistry, and Pharmacology & Therapeutics etc. Dr. Qin has secured substantial research funding from prestigious organizations including the National Health and Medical Research Council, National Heart Foundation, National Drug Discovery Centre, Diabetes Australia, CASS Foundation, Therapeutic Innovation Australia, JDRF etc. Dr. Qin's outstanding leadership and scholarly achievements have been duly recognized through the receipt of over 20 prestigious awards, including the Hypertension Australia Mid-Career Award (2023), Monash Talent Accelerator Fellow (2023), MRFF-Industry Fellow (2021), Future Research Leader (2020), and the Asian Australian Leadership Award (Basic Scientist, 2019), among others. For more information, please visit: https://www.monash.edu/mips/themes/drug-discovery-biology/labs/cardiovascular-pharmacology.

Prof. Pui Man Maggie Hoi has a background in cardiovascular and cerebrovascular pharmacology. She graduated from Cambridge University, the United Kingdom, with a Ph.D. in Pharmacology. She currently holds the position of Associate Professor at the Institute of Chinese Medical Sciences and Faculty of Health Sciences in the University of Macau. Her research focuses on investigating endothelial dysfunctions and inflammation, particularly exploring the interactions between reactive astrocytes and microglia and their impact on brain endothelial cells, encompassing neuroinflammation in aging and pathophysiological conditions such as Alzheimer's disease (AD), stroke, and diabetes. She utilizes various transgenic animal models (mouse, zebrafish, drosophila) and multicellular co-culture models to study acute and chronic inflammatory responses in various diseases. In addition, she is also interested in drug discovery, specifically focusing on identifying anti-inflammatory small molecules and natural compounds derived from traditional Chinese medicine (TCM). She is the principle investigator for multiple research projects including projects funded by the Macau SAR Science and Technology Development Fund (FDCT), the National Natural Science Foundation of China (NSFC) (Joint scheme), the Development of Science and Technology of Guangdong Province (GDST) (Joint scheme), and the University of Macau Research Grant (UM-MYRG & UM-CRG).

Simon Ming Yuen LEE is currently Chair Professor of Biomedical Sciences in Department of Food Science and Nutrition, and State Key Laboratory of Chemical Biology and Drug Discovery, The Hong Kong Polytechnic University. Simon obtained PhD degree in biochemistry from The Chinese University of Hong Kong. His research interests lie in the discovery of drug-like agents from natural products including small molecules and biologics for use in various therapeutic areas, including brain disorder and neurodegenerative diseases. His dedication to education and research in the fields of omics, pharmacology and toxicology has leaded to over 360 scholarly articles, including Nature, Nature Genetics, Nature Communications (4×) and Science Advances. Simon is in stanford university's list of top 2% of most-cited scientists in Pharmaceutical Science and Biology (with h-index: 65 from Scopus). Simon is a life member of Clare Hall, University of Cambridge. He has served as an editorial board member for numerous international journals including Chinese Medicine, Antioxidants, Journal of Ethopharmacology, and Water Biology and Security.

Her main research direction is pharmacological research on traditional Chinese medicine including cerebrovascular diseases, diabetes ulcers, and craniocerebral injuries. She received the title of North Brain Young Scholar from Beijing Brain Science and Brain Research Center (2020), and was selected for the 2021 Young Talent Promotion Project of the Chinese Society of Traditional Chinese Medicine. Hosted 6 national level projects such as the National Natural Science Foundation of China General Program. As the first author or corresponding author, she published more than 30 papers, and received 4 prizes, including the First Prize of Science and Technology of the Chinese Academy of Traditional Chinese Medicine, Additionally, she was authorized 3 invention patents, participated in the compilation of 3 monographs and invited to give presentations at international academic conferences.